“We need to design better products that work for everyone.” To that end, Medtronic has also opened up a lab in Colorado with the goal of testing future devices on a more diverse set of skin tone ...

Medtronic plc MDT is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company’s adjusted earnings of $1.23 exceeded the ...

About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...

Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

However, now only the Medtronic Revo system has obtained FDA approval, while the other products have Conformité Européenne (CE) marks and currently Advisa MRI, Accent MRI, and Evia Pro MRI are ...

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson’s rating is ...

which is part of the Medtronic Cardiovascular Portfolio. "The potential of Affera is limitless. We will continue to fulfill our commitment to innovation, including new indications, to advance ...

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of ...